| Literature DB >> 35415189 |
Katerina S Cheliotis1, Christopher P Jewell2, Carla Solórzano1, Britta Urban1, Andrea M Collins1, Elena Mitsi1, Sherin Pojar1, Elissavet Nikolaou1, Esther L German1, Jesús Reiné1, Stephen B Gordon1,3, Simon P Jochems1, Jamie Rylance1, Daniela M Ferreira1.
Abstract
Streptococcus pneumoniae (pneumococcus) is the most commonly identified bacterial cause of pneumonia and the leading infectious cause of death in children under 5 years of age worldwide. Pneumococcal disease follows a seasonal pattern with increased incidence during winter. Pneumonia burden is also associated with poor air quality. Nasopharyngeal carriage of the bacterium is a pre-requisite of invasive disease. We aimed to determine if susceptibility to nasopharyngeal pneumococcal carriage varied by season and which environmental factors might explain such variation. We also evaluated the influence of sex on susceptibility of carriage. We collated data from five studies in which human volunteers underwent intranasal pneumococcal challenge. Generalised linear mixed-effects models were used to identify factors associated with altered risk of carriage acquisition, specifically climate and air-quality data. During 2011-2017, 374 healthy adults were challenged with type 6B pneumococcus. Odds of carriage were significantly lower in males (OR, 0.61; 95% CI, 0.40-0.92; p=0.02), and higher with cooler temperatures (OR, 0.79; 95% CI, 0.63-0.99; p=0.04). Likelihood of carriage was also associated with lower concentrations of local fine particulate matter concentrations (PM2.5) and increased local rainfall. In contrast to epidemiological series, experimental challenge allowed us to test propensity to acquisition during controlled exposures; immunological explanations for sex and climatic differences should be sought.Entities:
Year: 2022 PMID: 35415189 PMCID: PMC8995542 DOI: 10.1183/23120541.00586-2021
Source DB: PubMed Journal: ERJ Open Res ISSN: 2312-0541
Demographics data for each clinical trial and pooled data
|
|
|
|
|
|
|
|
|
|
| To establish >40% carriage using Spn6B and Spn23F; participants inoculated with Spn6B included in this analysis (started 2011) | 86 | 23 (22–34) | 49 (57.0) female | January (20) | 45.3 | 89 929 (33 999–104 500) |
|
| To define the effect of LAIV on EHPC; study control group included in this analysis (started 2016) | 62 | 21 (19–22) | 32 (51.6) female | January (19) | 38.7 | 75 575 (70 166–81 499) |
|
| As study 1 | 163 | 21 (19–22) | 89 (54.6) female | January (35) | 49.7 | 81 249 77 833–85 333) |
|
| Pilot study of repeated mucosal sampling on EHPC (started 2015) | 18 | 28 (22–34) | 12 (66.7) female | July (15) | 38.9 | 80 823 (77 166–84 333) |
|
| To evaluate the effect of PCV on EHPC compared to hepatitis A vaccine; study control group included in this analysis (started 2013) | 45 | 23 (19–23) | 28 (62.2) female | February (3) | 44.4 | 82 938 (77 833–88 583) |
|
| |||||||
|
| 374 | 22 (19–22) | 210 (56.2) female | January (74) | 45.7 | 82 502 (74 333–85 333) | |
Spn6B: serotype 6B pneumococcus; Spn23F: serotype 23F pneumococcus; +LAIV: live attenuated influenza vaccine; EHPC: experimental human pneumococcal carriage; PCV: pneumococcal conjugate vaccine.
FIGURE 1Distribution of data across months of the year for the pooled cohort. No volunteers were inoculated during the month of April in any study.
FIGURE 2a) The number of carriage positive and carriage negative volunteers in each inoculation month. b) The number of carriage positive and carriage negative volunteers in each age category. c) The number of female (f) and male (m) volunteers in the pooled dataset with positive and negative pneumococcal carriage status. d) The number of female (f) and male (m) volunteers in each study with positive and negative pneumococcal carriage status.
FIGURE 3Percentage of carriage positive volunteers on which pneumococcal carriage was first detected at 2, 7, 14 or 27 days after initial inoculation across each inoculation month (a), each age category (b) and in females (f) and males (m) (c).
Log odds, standard error values and p-values obtained from the generalised linear mixed-effects model
|
|
|
| |
|
| −0.502 | 0.214 | 0.019 |
|
| −0.248 | 0.128 | 0.052 |
|
| −0.239 | 0.118 | 0.043 |
|
| −0.175 | 0.113 | 0.124 |
#: particulate matter <2.5 µm in diameter.
Correlation matrix for variables included in generalised linear mixed-effects model
|
|
|
| |
|
| 1 | 0.44 | 0.36 |
|
| 0.44 | 1 | 0.11 |
|
| 0.36 | 0.11 | 1 |
#: particulate matter <2.5 µm in diameter.